Michael Gelband’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Michael Gelband’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-30,000	Closed	-$143K	–	1400
2019 Q1	$143K	Buy	+30,000	New	+$78.7K	0.01%	596

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Michael Gelband's SRNE Position: Q4 2022 in Review

Michael Gelband sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 44,233 shares — an estimated $69K sold.

Michael Gelband first reported a position in SRNE in Q3 2020 and held it in 5 quarters. The position peaked at $740K in Q2 2021. 223 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

Michael Gelband reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Michael Gelband sold 44,233 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $69K.
Michael Gelband first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 5 quarters.
Michael Gelband's Sorrento Therapeutics, Inc. position peaked at $740K in Q2 2021.
223 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on ExodusPoint Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.